[1]李 臻,李 鑫,白亮亮,等.DEB-TACE治疗消化道肿瘤肝转移的初步观察[J].郑州大学学报(医学版),2019,(05):658-662.[doi:10.13705/j.issn.1671-6825.2019.06.103]
 LI Zhen,LI Xin,BAI Liangliang,et al.Clinical study of DEB-TACE in treatment of digestive tract tumor with liver metastases[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(05):658-662.[doi:10.13705/j.issn.1671-6825.2019.06.103]
点击复制

DEB-TACE治疗消化道肿瘤肝转移的初步观察()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年05期
页码:
658-662
栏目:
系列研究
出版日期:
2019-09-20

文章信息/Info

Title:
Clinical study of DEB-TACE in treatment of digestive tract tumor with liver metastases
作者:
李 臻李 鑫白亮亮纪 坤詹鹏超任建庄段旭华韩新巍
郑州大学第一附属医院放射介入科 郑州 450052
Author(s):
LI ZhenLI XinBAI LiangliangJI KunZHAN PengchaoREN JianzhuangDUAN XuhuaHAN Xinwei
Department of Interventional Radiology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052
关键词:
载药微球 化疗栓塞 肝转移 介入治疗
Keywords:
drug-eluting bead chemoembolization liver metastasis interventional therapy
分类号:
R735
DOI:
10.13705/j.issn.1671-6825.2019.06.103
摘要:
目的:探讨载药微球(DEB)-经动脉化疗栓塞术(TACE)治疗消化道肿瘤肝转移的可行性、安全性及近期疗效。方法:48例经影像学或病理学确诊的消化道肿瘤肝转移患者,其中25例接受DEB-TACE治疗,23例接受传统TACE(c-TACE)治疗。DEB-TACE组男20例,女5例,年龄31~75(59.9±3.3)岁,包括结直肠癌肝转移17例、胃癌肝转移8例。c-TACE组中男15例,女8例,年龄27~77(60.1±10.0)岁,包括结直肠癌肝转移16例,胃癌肝转移7例。比较两组患者术前、术后1周、术后1个月肝肾功能、凝血功能、血常规等指标。术后1、3、6个月复查影像学(CT/MRI平扫+增强),按改良实体瘤疗效评价标准评价近期疗效。结果:DEB-TACE组和c-TACE组患者术后1周均表现出ALT及白细胞一过性升高,术后1、3、6个月的疾病客观缓解率(80%、52%、27%vs 65%、78%、13%)和控制率(84%、64%、41%vs 78%、57%、22%)差异无统计学意义(P>0.05)。两组患者均无严重并发症发生,栓塞后综合征(恶心、呕吐、腹痛、发热)发生率差异亦无统计学意义(P>0.05)。结论:DEB-TACE治疗消化道肿瘤肝转移的近期疗效肯定,且安全、可行。
Abstract:
Aim:To explore the feasibility, safety and short-term efficacy of drug-eluting bead(DEB)and transarterial chemoembolization(TACE)in the treatment of digestive tract tumor with hepatic metastases.Methods:The data of 48 patients with liver metastases from digestive tract cancer were retrospectively analyzed. The patients were allocated into DEB-TACE group(25 cases)and c-TACE group(23 cases). There were 20 males and 5 females in the DEB-TACE group, aged 31-75(59.9±3.3)years, including 17 cases of colorectal cancer liver metastasis and 8 cases of gastric cancer liver metastasis. There were 15 males and 8 females in the c-TACE group, aged 27-77(60.1±10.0)years, including 16 cases of colorectal cancer liver metastasis and 7 cases of gastric cancer liver metastasis. The liver and kidney function, blood coagulation, blood routine indicators of the two groups before the operation, 1 week after surgery, and 1 month after surgery, were compared. The patients underwent radiography(CT/MRI plain scan + enhancement)at 1 month, 3 months, and 6 months after operation, and were evaluated according to the modified response evaluation criteria in solid tumors.Result:It showed that ALT and leukocytes increased transiently 1 week after operation in the two groups. The disease alleviation rate of DEB-TACE group and c-TACE group at 1,3,6 months after operation was(80%,52%,27%)vs(65%,78%,13%),and control rate was(84%,64%,41%)vs(78%,57%,22%).The differences in disease alleviation rate and control rate between the two groups was not significant(P>0.05). There were no serious complications in both groups, and the difference in the incidence of post-embolic syndrome(nausea, vomiting, abdominal pain, fever)between the two groups was not significant(P>0.05).Conclusion:The short-term efficacy of DEB-TACE in the treatment of digestive tract tumor with hepatic metastases is certain,safe and feasible.

参考文献/References:

[1] 王保信,张锐,胡新华,等.雷替曲塞联合经肝动脉化疗栓塞术治疗晚期大肠癌肝转移的效果观察[J].临床肝胆病杂志,2016,32(4):742
[2] DE BAERE T,DESCHAMPS F,TERIITHEAU C,et al.Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results[J].J Vasc Interv Radiol,2008,19(6):855
[3] LENCIONI R,LLOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52
[4] BHUTIANI N,MARTIN RC 2nd.Transarterial therapy for colorectal liver metastases[J].Surg Clin North Am,2016,96(2):369
[5] AJANI JA,D'AMICO TA,ALMHANNA KA,et al.Gastric cancer, version 3.2016,NCCN clinical practice guidelines in oncology[J].J Nat Compr Canc Netw,2016,14(10):1286
[6] TAKAYASU K,ARII S,IKAI I,et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8 510 patients[J].Gastroenterology,2006,131(2):461
[7] 李炜,倪才方.常见血管内栓塞材料的临床应用进展[J].中华介入放射学电子杂志,2018,6(4):347
[8] 张辉,张庆桥,徐浩,等.国产CalliSpheres载药微球治疗原发性肝癌的疗效评价[J].临床放射学杂志,2019,38(3):530
[9] CUCCHETTI A,TREVISANI F,CAPPELLI A,et al.Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemoembolization for hepatocellular carcinoma[J].Dig Liver Dis,2016,48(7):798
[10]AKINWANDE O,SCOGGINS C,MARTIN RC.Early experience with 70-150 μm irinotecan drug-eluting beads(M1-DEBIRI)for the treatment of unresectable hepatic colorectal metastases[J].Anticancer Res,2016,36(7):3413
[11]IEZZI R,MARSICO VA,GUERRA AA,et al.Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads(DEBIRI)and capecitabine in refractory liver prevalent colorectal metastases: a phase Ⅱ single-center study[J].Cardiovasc Intervent Radiol,2015,38(6):1523
[12]FIORENTINI G,ALIBERTI C,TILLI M,et al.Intra-arterial infusion of irinotecan-loaded drug-eluting beads(DEBIRI)versus intravenous therapy(FOLFIRI)for hepatic metastases from colorectal cancer:final results of a phase Ⅲ study[J].Anticancer Res,2012,32(4):1387
[13]AKINWANDE O,DENDY M,LUDWIG JM,et al.Hepatic intra-arterial injection of irinotecan drug eluting beads(DEBIRI)for patients with unresectable colorectal liver metastases:a systematic review[J].Surg Oncol,2017,26(3):268

相似文献/References:

[1]王振军,胡鸿涛,黎海亮#.肝动脉热灌注化疗栓塞对原发性肝癌碘化油沉积及疗效的影响[J].郑州大学学报(医学版),2015,(05):718.

备注/Memo

备注/Memo:
【基金项目】河南省高等学校重点科研攻关项目(17A320011)
【作者简介】韩新巍,通信作者,男,1958年6月生,博士,主任医师,研究方向:各类疾病的介入治疗,E-mail:hanxinwei2006@163.com
更新日期/Last Update: 2019-09-20